Molecular Remission in PML/RARa-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy

Molecular Remission in PML/RARa-Positive Acute Promyelocytic Leukemia by Combined MV-trans Retinoic Acid and Idarubicin (AIDA) Therapy

Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARa Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter ‘‘AIDA’’ Trial

Although the majority of patients with acute promyelocytic leukemia (APL) are potentially cured by treatments combining all-trans retinoic acid (ATRA) and chemotherapy (CHT), a sizable proportion (around30%)will relapseduring follow-up.Retrospective molecular monitoring studies using reverse transcriptasepolymerase chain reaction (RT-PCR) for the specific PML/RARa fusion gene, have shown that a...

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Therapy of Molecular Relapse in Acute Promyelocytic Leukemia

Fourteen patients with PML/RARa-positive acute promyelocytic leukemia (APL) were given salvage therapy at the time of first molecular relapse. All patients had achieved first molecular remission after the AIDA protocol (all-trans retinoic acid [ATRA] 1 idarubicin) and were being prospectively monitored by reverse transcriptase-polymerase chain reaction (RT-PCR). Molecular relapse was defined as...

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.

All-trans-retinoic acid (ATRA) has greatly modified the prognosis of acute promyelocytic leukemia; however, the role of maintenance in patients in molecular complete remission after consolidation treatment is still debated. From July 1993 to May 2000, 807 genetically proven newly diagnosed acute promyelocytic leukemia patients received ATRA plus idarubicin as induction, followed by 3 intensive ...

MYELOID NEOPLASIA Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein

Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA). The authors of previous studies have implicated the ubiquitin-proteasome pathway a...